Selective Killing of Prostate Tumor Cells by Cytocidal Viruses
Abstract
The goal is to develop novel vectors for therapy of prostate tumors based on vesicular stomatitis virus (vsv) . VSV kills many tumor cells more effectively than normal cells, due in part to defects in the antiviral response in tumor cells. The novelty in our approach is our ability to enhance the selectivity of killing of tumor cells versus normal cells by manipulating the viral genes that control the antiviral interferon response. Aim 1 is to identify mutations in VSV genes that enhance the differential killing of prostate tumor cells versus normal cells. Aim 2 is to identify VSV mutants that enhance the antiviral interferon response in prostate cells. Aim 3 is to determine whether VSV mutants have greater efficacy and safety than wild-type VSV in reducing prostate tumors in nude mice. In this reporting period, we have largely completed the experiments in Aims 1 and 2 for normal prostate cells and the tumor cells (LNCaP and PC-3), and have identified several mutant viruses with the desired properties. In addition, we have preliminary data on Aim 3, indicating that one of the mutant viruses is an effective, and safer vector for treating LNCaP tumors in nude mice.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2003
- Accession Number
- ADA415313
Entities
People
- Douglas S. Lyles
- Maryam Ahmed
- Scott D. Cramer
Organizations
- Wake Forest University